MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ambrisentan

CAS No. : 177036-94-1

MCE 站：Ambrisentan

产品活性：Ambrisentan 是一种选择性的ET A型受体 (ETAR) 拮抗剂。

研究领域：GPCR/G Protein

作用靶点：Endothelin Receptor

In Vitro: Ambrisentan is an endothelin type A receptor antagonist. Ambrisentan induces Nrf2 activation. Endothelial permeability increased in BMEC monolayers at 24 h of hypoxia exposure and compared to vehicle control, Ambrisentan attenuates hypoxia-induced BMEC leak. These results are reversed when prior to treatment BMEC are transfected with siRNA against Nrf2.

In Vivo: In the Ambrisentan group, hepatic hydroxyproline content is significantly lower than in the control group (18.0 μg/g±6.1 μg/g vs 33.9 μg/g±13.5 μg/g liver, respectively, P=0.014). Hepatic fibrosis estimated by Sirius red staining and areas positive for α-smooth muscle actin, indicative of activated hepatic stellate cells, are also significantly lower in the Ambrisentan group (0.46%±0.18% vs 1.11%±0.28%, respectively, P=0.0003; and 0.12%±0.08% vs 0.25%±0.11%, respectively, P=0.047). Moreover, hepatic RNA expression levels of procollagen-1 and tissue inhibitor of metalloproteinase-1 (TIMP-1) are significantly lower by 60% and 45%, respectively, in the Ambrisentan group. Inflammation, steatosis, and endothelin-related mRNA expression in the liver are not significantly different between the groups. Ambrisentan attenuates the progression of hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing procollagen-1 and TIMP-1 gene expression. Ambrisentan did not affect inflammation or steatosis.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Diabetes Related Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Endocrinology Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Endothelin 1 (swine, human)  |  BQ-788 sodium salt  |  Bosentan  |  BQ-123  |  Atrasentan hydrochloride  |  Sparsentan  |  Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate  |  Sulfisoxazole  |  Atrial Natriuretic Peptide (ANP) (1-28), rat  |  Avosentan  |  Zibotentan  |  Darusentan  |  Sitaxsentan sodium  |  A-192621  |  IRL 2500  |  BQ-3020 TFA  |  IRL-1620  |  Nebentan  |  Tezosentan  |  ABT-546  |  Aminaftone  |  Aprocitentan D4  |  BMS-248360

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。